Mesoblast (NASDAQ:MESO) Upgraded by Cantor Fitzgerald to “Strong-Buy” Rating

Cantor Fitzgerald upgraded shares of Mesoblast (NASDAQ:MESO) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports.

A number of other equities research analysts have also commented on the company. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Piper Sandler reiterated an “overweight” rating and issued a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Stock Performance

MESO opened at $14.71 on Tuesday. The firm’s 50-day moving average price is $18.03 and its 200-day moving average price is $12.25. Mesoblast has a 52-week low of $1.99 and a 52-week high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Investors Weigh In On Mesoblast

Several hedge funds have recently bought and sold shares of MESO. Bank of America Corp DE raised its stake in shares of Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company’s stock worth $5,756,000 after buying an additional 272,595 shares during the period. Oaktree Capital Management LP acquired a new position in Mesoblast in the 4th quarter valued at $3,556,000. Strategic Financial Concepts LLC acquired a new position in Mesoblast in the 4th quarter valued at $2,744,000. Prosperity Wealth Management Inc. raised its stake in Mesoblast by 2.0% in the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock valued at $1,846,000 after purchasing an additional 1,795 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares during the last quarter. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.